L-744832
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


L-744832
Description:
L-744832 is a farnesyl transferase inhibitor. L-744832 effectively inhibits the farnesylation of H-Ras and N-Ras, but has little effect on K-Ras treatment. L-744832 not only directly targets the oncogenic pathway by inhibiting Ras farnesylation, but also enhances radiosensitivity by restoring TGF-β signaling through epigenetic reprogramming. L-744832 can induce cell cycle arrest and apoptosis. L-744832 can be used in combination therapy studies for Ras-driven tumors such as pancreatic cancer[1][2].UNSPSC:
12352200Target:
Apoptosis; Farnesyl Transferase; Ras; TGF-β ReceptorRelated Pathways:
Apoptosis; GPCR/G Protein; MAPK/ERK Pathway; Metabolic Enzyme/Protease; TGF-beta/SmadApplications:
Cancer-Kinase/proteaseField of Research:
CancerSmiles:
O=C(OC(C)C)[C@@H](NC([C@@H](OC[C@@H](NC[C@@H](N)CS)[C@@H](C)CC)CC1=CC=CC=C1)=O)CCS(=O)(C)=OMolecular Formula:
C26H45N3O6S2Molecular Weight:
559.78References & Citations:
[1]Song SY, et al. K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells. Neoplasia. 2000 May-Jun;2 (3) :261-72. |[2]Alcock RA, et al. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2. Oncogene. 2002 Nov 7;21 (51) :7883-90.Shipping Conditions:
Room temperatureScientific Category:
Biochemical Assay ReagentsClinical Information:
No Development ReportedIsoform:
H-Ras; N-RasCAS Number:
[160141-09-3]
